Background. Quantitative cytomegalovirus (CMV) DNA-specific polymerase chain reaction (PCR) analysis is widely used as a surveillance method for hematopoietic stem cell transplant (HCT) recipients. However, no CMV DNA threshold exists in bronchoalveolar lavage (BAL) to differentiate pneumonia from pulmonary shedding.
The role of quantitative polymerase chain reaction (PCR) analysis in the diagnosis of cytomegalovirus (CMV) pneumonia after hematopoietic stem cell transplantation (HCT) remains undefined [1] [2] [3] . In 1988, CMV detection by rapid culture of bronchoalveolar lavage (BAL) fluid became the mainstay of diagnosis for CMV pneumonia [4] . However, while CMV DNA-specific PCR is widely used as a surveillance method for blood and serum specimens and because many laboratories have largely abandoned traditional virologic techniques, the usefulness of quantitative PCR of BAL as a diagnostic tool for CMV pneumonia is poorly defined [5] [6] [7] [8] , and the recently updated international definition guidelines provide only limited definitive evidence for using PCR as an acceptable test for disease diagnosis [9, 10] . The key reason for the dilemma is that the presence of CMV DNA may not constitute disease, owing to the well-described phenomenon of pulmonary CMV shedding [11, 12] . Studies in the early 1990s established that CMV can be detected by culture in BAL fluid from asymptomatic bone marrow transplant recipients and that pulmonary shedding is predictive for subsequent CMV pneumonia [11, 12] . Further complicating this picture is the uncertain role of CMV as either a pathogen or bystander, when detected in BAL specimens from patients with other confirmed pathogens [1, 9, [13] [14] [15] . Detection of CMV DNA may also be influenced by blood contamination in patients with pulmonary hemorrhage, and the viral load may differ between lung compartments. Studies of CMV DNA-specific PCR of BAL fluid from HCT recipients have found a high negative predictive value [16] , and a small study showed differences in viral load between pneumonia and pulmonary shedding [17] , but a threshold value with a high positive predictive value in current CMV pneumonia prevalence situations has remained elusive. cohort of subjects with CMV pneumonia after HCT diagnosed between March 1988 and December 2014 at the FHCRC to 3 separate control cohorts of HCT recipients with available BAL samples for PCR: (1) patients who had radiographically proven infectious pneumonia but were found to be negative for CMV standard virologic testing, (2) patients with a diagnosis of idiopathic pneumonia syndrome (IPS) without occult pathogens [18] , and (3) a cohort of asymptomatic patients who underwent HCT between 1988 to 1989 and, according to standardized protocol, had BAL performed 35 days after transplantation as part of a prospective study (the latter cohort served as a comparison group for evaluating BAL-associated CMV load in asymptomatic pulmonary shedders) [12] . All control patients were at risk for CMV pneumonia (seropositive recipient or donor).
Patients with CMV pneumonia had symptoms or signs of pneumonia during the post-HCT period, were found to be positive for CMV on diagnostic BAL testing by standard virologic criteria (ie, positive results of shell vial or conventional culture or direct fluorescent antibody [DFA] testing) [9] and had stored BAL samples available for analysis. Patients with non-CMV infectious pneumonia had radiographic and clinical signs of pneumonia that led to a BAL, had negative results of all standard BAL tests for CMV at the time of their diagnosis, had another pathogen identified, and were known to be CMVseropositive recipients. Patients with IPS underwent an extensive diagnostic panel and had negative results of standard CMV cultures and all other tests (results of CMV-specific PCR were analyzed as the variable of interest in this study) [18] . Patients in the asymptomatic cohort (normal chest radiographic findings and absence of cytopenias) agreed to undergo a standard BAL for research purposes between days 35 and 45 after HCT [12] .
Transplantation and Supportive Care Procedures
Subjects were followed by means of standard center-based pretransplantation and posttransplantation regimens, but these varied by transplantation year [19, 20] . Strategies to prevent CMV infection have varied over time, with preemptive therapy first given on the basis of results of rapid cultures [21] , followed by pp65 antigenemia assays [22] and PCR [23] . The duration of acyclovir/valacyclovir prophylaxis against infection due to herpes simplex virus types 1 and 2 and varicella zoster virus was 1 month before 1998 and at least 1 year thereafter [24] . All patients received standard prophylactic antimicrobial and antifungal agents during follow-up [19] . The presence of antiviral drugs with activity against CMV at the time of diagnosis of pneumonia was recorded. Any patient found to have CMV pneumonia based on results of standard virologic tests of BAL fluid received treatment with intravenous ganciclovir or foscarnet for a minimum of 2-3 weeks as induction therapy and 2-4 weeks as maintenance therapy; most patients also received pooled or CMV-specific intravenous immunoglobulin G [25] .
BAL Evaluation
HCT recipients who present with radiographic and clinical signs of pneumonia routinely undergo evaluation by bronchoscopy, using standard procedures based on international consensus guidelines [26, 27] . If a patient underwent multiple BALs over time during a pneumonia event, only the first BAL specimen was evaluated in this study. The presence of pulmonary hemorrhage at the time of the BAL was recorded, based on the pathology report. Some patients had distinctly different radiographic findings and may have undergone 2 separate BALs with separate virologic and microbiologic evaluation during the same procedure; these samples were evaluated separately. Corresponding CMV DNA plasma viremia was determined in archived samples obtained close (within 7 days) to the bronchoscopy.
All BAL samples underwent CMV testing by 24-hour and 48-hour shell vial cultures and conventional cultures (rhesus monkey kidney, human foreskin fibroblasts, and A-549 cells); DFA and cytopathologic evaluation (for the presence of inclusion bodies) was done in a subset of patients [9] . The presence of other pathogens was evaluated by a broad diagnostic panel, as described elsewhere [18] ; multiplex respiratory virus PCR was done on a subset of BAL specimens [28] .
Archived BAL aliquots from study subjects in all cohorts (stored as temperatures ranging from −20°C to −80°C) were tested by quantitative CMV DNA-specific PCR, using gB/pp65 primers [29] adapted for BAL fluid: each 30 μL of PCR mixture contained 15 μL of 2× QuantiTect Multiplex PCR master mix (Qiagen, Valencia, CA), 415 nM of each primer, 100 nM of each probe, Exo internal control, and 10 μL of extracted DNA. Results were expressed as IU per milliliter. The PCR cycling steps were as follows: 1 cycle at 50°C for 2 minutes, 1 cycle at 95°C for 15 minutes, and 45 cycles of 94°C for 1 minute and 60°C for 1 minute. The lower limit of reproducible quantitation of this assay was 83.3 IU/mL; unquantifiable positive results below this threshold were assigned a level of 41.65 IU/mL. To confirm BAL cellularity and the quality of DNA extraction [30, 31] , as well as for quantitation relative to cellular content, we amplified the β-globin gene from BAL samples as previously described [32] . If a patient had multiple BAL specimens from different locations during the same bronchoscopy procedure, CMV DNA-specific PCR results were averaged, unless otherwise indicated. BAL samples from the group with CMV pneumonia that did not amplify were tested by alternate primers.
Statistical Analysis
Characteristics of study subjects were summarized, and transplantation and other demographic factors were compared using either the Fisher exact, for categorical variables, or the Student t test, for continuous variables. Median CMV loads (log 10 ) between groups were compared using the Mann-Whitney test. Sensitivity and specificity were estimated on the basis of different viral loads, and the best CMV load cutoff for CMV pneumonia was determined using a receiver operating characteristic (ROC) curve. For purposes of the ROC curve, we included all patients in the CMV pneumonia group with a BAL specimen that tested positive; all subjects in the comparison cohorts tested negative by standard CMV tests (ie, viral culture, shell vial, DFA, and cytology). To address the potential effects of anti-CMV therapy on BAL viral load, ROC curves were generated using only those patients who were not receiving active therapy at the time of BAL. Predictive models were developed by calculating the positive and negative predictive values of different viral load thresholds for a range of prevalence scenarios of CMV pneumonia among patients undergoing BAL evaluation. We also compared CMV DNA log 10 viral load in BAL specimens from patients who tested positive by the different standard tests for CMV pneumonia.
RESULTS

Study Subjects
A total of 271 subjects met eligibility criteria for inclusion in this study: 132 symptomatic subjects with CMV pneumonia, 118 symptomatic subjects with non-CMV pneumonia, and 21 asymptomatic research subjects who had either been tested or had specimens available for PCR testing ( Table 1) . As expected on the basis of the cohort definitions and period of transplantation, differences in characteristics were seen for graft source and intensity of the conditioning regimen. Among cases, 21 patients had multiple pulmonary locations lavaged on the same day. Of Figure 1A ). Two patients in the CMV pneumonia cohort had a negative CMV DNA-specific PCR result; both tested positive by the shell vial assay but no virus was isolated from the cultures, both had negative cytology findings, neither was tested by DFA, and both were negative by PCR using different primers. Figure 1) . Storage time did not appear to affect viral load (Supplementary Figure 2) .
Analysis of Possible Effect Modifiers
Copathogens, Radiographic Presentation, and Multiple Locations
Among patients with CMV pneumonia, the median viral load was not significantly different between patients who did and those did not have copathogens detected (3.8 log 10 IU/mL [IQR, 2.5-5.6 log 10 IU/mL] and 4.3 log 10 IU/mL [IQR, 3.0-6.2 log 10 IU/mL], respectively; Figure 1B) ; there were also no statistically significant differences between autologous and allogeneic transplant recipients in these groups (Supplementary Figure 3) . Further analysis of radiographic presentation (Figure 2A ) and copathogens by type (fungal, viral, and bacterial; Figure 2B ) also did not show significant differences. An analysis that combined radiographic presentation (focal nodular vs diffuse/ ground glass) and the detection of fungal pathogens showed no significant differences among patients with probable pulmonary aspergillosis and those who tested negative for aspergillus galactomannan (Supplementary Figure 4) .
Pulmonary Hemorrhage
To determine whether the presence of pulmonary hemorrhage in patients with CMV DNAemia at the time of BAL affected the BAL viral load, we compared viral loads in plasma and BAL specimens from patients with and those without pulmonary hemorrhage. There was no difference in viral load relative to the presence of pulmonary hemorrhage both in patients with CMV pneumonia and those with non-CMV pneumonia ( Figure 2C ).
Viral Load in Lung Locations
Among 16 patients who underwent 2 separate BALs during the same session to evaluate 2 different pulmonary locations, the median difference in viral loads between locations did not differ, even if radiographic presentations differed significantly, but a few outliers were observed (Supplementary Figure 5) .
ROC Curve Analysis and Predictive Models
We constructed ROC curves of CMV DNA loads in BAL to determine thresholds that optimize both the sensitivity and specificity for CMV pneumonia. The ROC curves produced a high area under the curve (AUC) value. Figure 3A displays data for the CMV pneumonia group and the IPS and non-CMV pneumonia groups combined and Figure 3B compares patients with CMV pneumonia to asymptomatic control patients with cutoffs of 100 and 203 IU/mL, respectively. The exclusion of CMV pneumonia cases with copathogens did not improve the ROC curves or alter thresholds (data not shown).
We also constructed ROC curves for CMV BAL PCR findings adjusted for sample cellularity as IU/10 6 copies of β-globin. β-globin results were available for 125 patients with CMV pneumonia and 96 patients with IPS or non-CMV pneumonia. Overall, the AUCs were somewhat lower than that for findings in IU per milliliter (Supplementary Figure 6) .
We next analyzed whether antiviral treatment affected the viral load threshold. Antiviral agents (treatment duration, >3 days) were given either preemptively or presumptively during the diagnostic work-up for 15.2% of patients with CMV pneumonia and 30.5% with non-CMV pneumonia; an additional 8.5% and 3.4%, respectively, received treatment for up to 2 days. Supplementary Figure 7 shows an improved AUC when all antivirals were excluded (0.969 for findings in IU/mL and 0.956 for findings in IU/10 6 copies of β-globin). Results were similar when antivirals were used for up to 3 days (data not shown).
Using various CMV pneumonia prevalence estimates among patients undergoing BAL, we modeled the positive and negative predictive values for CMV pneumonia with different BAL DNA load thresholds (Figure 4 ). For instance, on the assumption of a CMV pneumonia prevalence of 10% among seropositive recipients undergoing BAL, the positive predictive value of a threshold of 500 IU/mL would be 45% ( Figure 4A ) and the negative predictive value would be >95% ( Figure 4B) . Predictive values were markedly improved among patients who did not receive any antiviral treatment at the time of PCR testing ( Figures 4C  and 4D ), resulting in positive predictive values of ≥60% for the 500 IU/mL threshold in very low prevalence situations.
Clinical Outcomes Relative to Viral Load Thresholds
We performed chart reviews of both controls and cases to examine the clinical implications of using various DNA thresholds in BAL fluid. Among control patients with pneumonia, 12 of 118 (10.2%) had a CMV DNA level of >500 IU/mL and 21 had levels between 100 and 500 IU/mL ( Figure 5A ). By using a threshold of 500 IU/mL, the majority of patients (9 of 12) who would have been classified on the basis of the 500 IU/ (2) focal ground-glass opacities (GGOs), (3) diffuse nodules, (4) diffuse GGOs. Outcomes in subjects with non-CMV pneumonia with a high viral load were evaluated by chart review. If multiple locations were lavaged on the same day, each is represented separately. One CMV pneumonia case with multiple BALs on the same day was excluded because BAL polymerase chain reaction (PCR) results could not be assigned to a specific BAL location. A total of 147 BALs were performed on 131 patients. B, Quantitative CMV load in BAL fluid from CMV pneumonia cases did not differ according to the absence (CMV only) or presence of any specific copathogen subset. Detection of Aspergillus galactomannan in the BAL or blood counted as detection of a fungal copathogen. Co-occurrence of fungal copathogens with other copathogens is denoted by green markers. If bacteria were present in addition to a viral copathogen, the BAL finding is grouped with viral copathogens but is denoted with an open marker. A total of 68 subjects had CMV only detected, 33 had a fungal copathogen detected, 22 had a viral copathogen detected, and 9 had a bacterial copathogen detected. C, Viral loads in cases and controls were similar in the presence or absence of pulmonary hemorrhage in patients with CMV DNAemia within 7 days of BAL (data are for 92 patients with CMV pneumonia and 33 controls). mL threshold as having CMV pneumonia had a clinical picture compatible with CMV pneumonia ( Figure 5B ). Conversely, use of the 500 IU/mL threshold would categorize 26% of patients (34 of 132) who received a diagnosis of CMV pneumonia as being CMV pulmonary shedders (2 tested negative, of whom neither had a copathogen detected; of the remaining 32 cases, 20 had a copathogen detected). Among the asymptomatic control subjects, 5 had levels of >500 IU/mL, of whom 2 developed subsequent CMV pneumonia 10 and 20 days after the BALs. Seventy-six percent of patients with a BAL viral load between 100 and 500 IU/mL had PCR-positive plasma specimens (Supplementary Materials).
Among the 132 cases of CMV pneumonia, overall mortality 90 days after diagnosis was 34.9%. The CMV load in BAL showed a poor correlation with overall and attributable mortality based on ROC analysis, and the exclusion of samples obtained from patients receiving antiviral agents did not significantly improve the AUC (Supplementary Figure 8) .
DISCUSSION
The study showed that viral loads of >500 IU/mL in BAL fluid reliably differentiate disease in situations of CMV prevalence. In certain high-prevalence situations and among patients who are not receiving anti-CMV agents, thresholds as low as 100 or 200 IU/mL may be associated with high positive and negative predictive values for CMV pneumonia. Our study also showed that pulmonary hemorrhage, copathogens, and radiographic presentation do not seem to affect these thresholds.
The use of the CMV DNA load in BAL to diagnose CMV pneumonia has been difficult to establish because asymptomatic shedding of CMV, both as DNA and as replicating virus, is a well-established phenomenon [11] , thereby complicating the interpretation of viral load results, especially in the context of copathogens. The present study is the first to establish diagnostic performance characteristics of different viral load thresholds in a cohort of patients who underwent a highly protocol-driven and unbiased diagnostic evaluation. Our data suggest that a threshold of 500 IU/mL of BAL fluid provides good positive and excellent negative predictive values for CMV pneumonia in most prevalence situations (Figure 4 ). It should be emphasized that the relevant prevalence figures should be based on the patients who require BAL evaluations for pulmonary infiltrates, rather than on all patients who are at risk on the basis of donor and recipient serostatus. Thus, a prevalence of 5%-20% maybe a reasonable estimate for most allogeneic transplant recipients at risk for CMV pneumonia. In particularly high-risk populations, such CMV-seropositive recipients of cord blood, those undergoing T-cell-depleted transplantation, or those for whom policies for performing BAL are more restrictive, lower thresholds may still provide positive predictive values of >50%, owing to the higher prevalence ( Figure 4) . A positive predictive value of approximately 50% is similar to that of BAL galactomannan positivity at the Food and Drug Administration-approved ≥0.5 level for invasive pulmonary aspergillosis with current prevalence figures of approximately 5%-10% [33] .
The interpretation of viral DNA results in BAL is complicated by a number of potential result modifiers, including the presence of pulmonary hemorrhage, copathogens, radiographic presentation, prior antiviral treatment, and cellularity in the BAL fluid. Our results suggest that, with the exception of antiviral treatment, none of these factors significantly altered the proposed thresholds. Whether pulmonary hemorrhage in the presence of viremia (by culture or DNA detection) affects diagnostic precision has not been addressed by the international definition guidelines. We did not find higher BAL viral loads in patients with concomitant viremia (Figure 2C ), suggesting that the viral loads in the lung and blood compartments are similar and primarily influenced by the level of immunosuppression. The analysis of patients with specific copathogens and/or radiographic presentation did not reveal different CMV levels from those in patients with CMV pneumonia without copathogens. Even patients with a focal nodular infiltrate and probable aspergillosis did not have significantly lower viral loads (Figure 2A ). This clinical presentation would not be considered classic for CMV pneumonia; however, nodular presentation is a known manifestation of CMV pneumonia [34] . This finding suggests that other copathogens or inflammatory conditions in the lung may increase the pulmonary viral load through the inflammatory cytokine milieu throughout the lung and that the viral load does not have a high diagnostic precision to determine whether CMV is a bystander in this situation. Prior receipt of ganciclovir or foscarnet for up to 3 days as preemptive or empirical Figure 5 . Clinical outcome in controls with cytomegalovirus (CMV)-specific polymerase chain reaction findings of >500 IU/mL in bronchoalveolar lavage (BAL) fluid (1 patient had idiopathic pneumonia syndrome [IPS], and 11 patients had non-CMV pneumonia). A, Viral loads of >500 IU/mL are shown by solid markers. The dotted line represents the threshold. B, The likelihood of subsequent development of CMV disease in subset. "Unlikely" denotes clinical presentation consistent with other causes, CMV-negative blood specimen; "possible" denotes CMV detected in blood specimen, treated with antiviral agents, other possible causes present; "probable" denotes CMV detected in blood specimen, no other causes of pneumonia in subsequent follow-up evaluations, clinical course consistent with viral pneumonia; and "proven" denotes subsequent CMV pneumonia diagnosed by standard criteria (eg, at autopsy). treatment affected the ROC curves and predictive values significantly (Supplementary Figure 7) . In contrast, BAL cellularity and the assessment of viral load per cellular content [17] did not provide obvious benefits, although this approach can be used as an alternative way to quantify the virus.
Given the well-established risk of subsequent CMV pneumonia [12] among patients with pulmonary CMV shedding with active CMV replication (as determined by shell vial cultures) and the well-established benefit of preemptive therapy in this situation [11] , we recommend a shorter course of antiviral treatment (eg, preemptive treatment with an induction dose for 2-3 weeks) for these shedding situations when both shell vial assay and PCR results are available. How to manage a patient with CMV DNA levels of <500 IU/mL in the absence of shell vial culture data (an increasingly common scenario) is more difficult to determine. Our data suggest that patients with extremely low levels (ie, <100 IU/mL) may not require treatment. However, patients with levels between 100 and 500 IU/ mL (particularly in the absence of other pathogens), high-risk patients, or those who underwent BAL in the absence of antiviral treatment might benefit from antiviral treatment. Given the low prevalence of this condition, it will be difficult to definitively study this question.
The study has several strengths, including the large number of CMV pneumonia cases, the presence of appropriate controls (including uninfected HCT recipients) with a complete diagnostic work-up, a high and largely unbiased rate of BAL performance, and the detailed evaluation of possible effect modifiers. Limitations include our inability to account for minor differences in dilution (although it does not matter with respiratory viruses) [35] [36] [37] and perhaps the smaller number of cases in specific subgroups of copathogens and focal radiographic presentation.
In conclusion, our study provides strong evidence that CMV DNA quantitation in BAL fluid by PCR can be used to differentiate CMV pneumonia from asymptomatic pulmonary shedding in HCT recipients. A cutoff of 500 IU/mL appears to be reasonable with current prevalence figures. However, different levels may be used in specific risk settings. Thus, the CMV DNA load in BAL fluid can be used by investigators and clinicians to reliably diagnose CMV pneumonia in clinical trials and at the bedside.
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